US Oncology Research Announces Schedule of Presentations at the 2018 American Society of Hematology Annual Meeting and Exposition
During the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, principal investigators from The US Oncology Network and US Oncology Research will demonstrate detailed results from 18 studies (two orals, 15 poster presentations and one late-breaking abstract) covering topics including multiple myeloma, plasma cell disorders, lymphoid malignancies, follicular lymphoma, non-Hodgkin lymphoma and more. The ASH Annual Meeting, a leading scientific event in malignant and non-malignant hematology, will be held December 1-4 in San Diego.
“We are proud once again to have numerous researchers from our community of oncologists showcase their work towards advancing cancer treatment options,” said Michael Seiden, MD, PhD, president of The US Oncology Network. “It is heartening to participate in this important event where research towards better patient outcomes is the priority, and I’m eager to learn the results from these promising studies.”
Habte Yimer, MD, US Oncology Research executive council member and medical oncologist and hematologist with Texas Oncology, co-authored a late-breaking abstract titled, “Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI),” which will be presented on Tuesday, December 4, 7:30-9:15am PT in Hall AB (San Diego Convention Center).
“I am honored to be a part of this study in which US Oncology Research was heavily involved and contributed to its success,” said Dr. Yimer. “Our practice accrued the largest number of patients to this study globally, and I am hopeful that it may be practice changing.”
Additionally, Dr. Yimer will present the initial efficacy and safety data on the treatment of multiple myeloma titled, “Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM).” The oral presentation will take place Saturday, December 1 at 12:15pm PT in Grand Ballroom 7 (Marriott Marquis San Diego Marina).
Jeff Sharman, MD, medical director of hematology research for The US Oncology Network and director of research at Willamette Valley Cancer Institute and Research Center, will present “A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL).” The oral presentation will be held on Sunday, December 2 at 12:45pm PT in Ballroom 20A (San Diego Convention Center).
Lastly, Robert Rifkin, MD, FACP, medical director of biosimilars and health economics and outcomes research (HEOR) committee member with McKesson and oncologists and hematologist with Rocky Mountain Cancer Centers, will present “Safety of Split Dosing Vs Standard Dosing Administration of Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study.” The poster presentation will be held Monday, December 3, 6:00-8:00pm PT in Hall GH (San Diego Convention Center).
The full schedule of US Oncology Research affiliated data presentations, including location and author information, can be found here. For more information or to interview a trial investigator, contact Claire Crye at 281.825.9927 or Claire.Crye@mckesson.com or Kerry Sinclair at 323.602.1096 or Kerry.Sinclair@gcihealth.com.
About US Oncology Research
US Oncology Research draws from a network of more than 1,000 experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and more than 150 locations, managing about 300 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 73,000 patients in over 1,600 trials and have played a role in more than 75 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. US Oncology Research is supported by McKesson Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005014/en/